Patient P-03430

Synthetic patientONX-7 · Day 121 · 75+ · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

92%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S14
Day 39 NP-02 recommended — Dietary Support Protocol NP-02
Day 40 Patient accepted — Started NP-02 in the companion
Day 50 No meaningful change — Dietary Support Protocol NP-02
Day 57 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 59 SC-12 recommended — Supportive Compound SC-12
Day 60 Patient accepted — Started SC-12 in the companion
Day 66 GI symptom burden −21% vs expected — Supportive Compound SC-12
Day 72 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 57.

Primary contributors, last 14 days

Toxicity-16
Treatment adherence-12
Inflammatory activity+4
Nutritional resilience-4
GI instability+3

What helped?

Dietary Support Protocol NP-02Day 39
Result: no meaningful change
Supportive Compound SC-12Day 59
Result: symptom burden −21%

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level

Daily log

2.3/10

worsening · -0.5 vs previous 14 d

Stress level

Daily log

6/10

improving · -0.3 vs previous 14 d

Pessimism score

Daily log

6.2/10

stable · -0.2 vs previous 14 d

Sleep quality

Wearable

23.2/100

worsening · -3.3 vs previous 14 d

Libido

Daily log

3/10

improving · +0.3 vs previous 14 d

HRV

Wearable

44.4 ms

stable · -0.3 vs previous 14 d

Toxicity

Blood

34.5/100

improving · -5.4 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 24 from the failing basin, 66 from restoration.

Would help

GI-04 GI Support Protocol
74% improved among 35 similar · onset 8 d · confidence 97%
ME-01 Monitoring Escalation
100% improved among 11 similar · onset 3 d · confidence 77%
DT-01 Dosing / Timing Recommendation
78% improved among 9 similar · onset 5 d · confidence 77%
More protein
GI -5.6 next day on high-intake days · n 24

Would not help

NP-02 Dietary Support Protocol
already tried, no meaningful change
AD-05 Adherence Support
only 25% improved among 12 similar
Keep fat low
GI +5.6 next day on high-intake days · n 27
Keep histamine low
GI +4.8 next day on high-intake days · n 24
Keep lactose low
GI +4 next day on high-intake days · n 25

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+5.6detractor · 95%
Protein
-5.6supporter · 95%
Histamine load
+4.8detractor · 95%
Lactose
+4detractor · 95%
Alcohol
-1.6no signal · 28%
Caffeine
+0.9no signal · 22%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 61 and rising
- WearableSleep 5.7 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 26/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 59
Autonomic recovery ↑45
- WearableResting HR 77 bpm
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.1 · butyrate capacity 26/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 45 ms
Sleep: 6.2 h
Steps: 6,150
Resting HR: 77 bpm

Daily log: GI score 61, nutritional resilience 39, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03105	21%	S12	AD-05	no change	60
P-03204	21%	S16	AD-05	improved	48
P-03034	20%	S14	AD-05	no change	30
P-03111	20%	S07	AD-05	no change	48
P-03351	20%	S07	AD-05	no change	51
P-03369	20%	S18	AD-05	no change	37
P-03424	20%	S12	AD-05	improved	41
P-03482	20%	S05	AD-05	no change	67
P-03122	19%	S13	AD-05	no change	40
P-03129	19%	S18	AD-05	no change	32
P-03158	19%	S17	AD-05	no change	37
P-03380	19%	S16	AD-05	improved	34